Introduction
Osteosarcoma, the predominant bone malignancy, primarily affects children and adolescents, with another susceptible group being individuals aged 60 and above.1–4 Recent data from the US National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program reported 3970 new cases of bone and joint cancers, resulting in 2170 deaths.5 Despite substantial focus on osteosarcoma’s epidemiology, prevalence, and prognostic factors,6–13 a global lack of comprehensive data persists, particularly in regions like Pakistan.14–16 The current treatment involves surgical resection and chemotherapy, with advanced-stage patients undergoing radiation therapy and metastatectomy for resectable pulmonary disease.17–20 Despite efforts elevating 5-year survival rates to 70% for localized…